Here’s what you should know.
1. Allergan’s linaclotide delayed release clinical data will focus on abdominal pain in irritable bowel syndrome with constipation.
2. Its Linzess data will focus on treatment satisfaction comparing an indirect treatment comparison and stool consistency and frequency data.
3. Allergan’s Viberzi data will focus on the drug’s effectiveness in treating irritable bowel syndrome with diarrhea.
4. Finally, its relamorelin data will focus on gastroparesis and cenicriviroc products to treat non-alcoholic steatohepatitis.
More articles on gastroenterology:
Gastrointestinal Specialists join Hampton Physicians Group — 3 insights
Gastro Health acquires Dr. Orlando Torres’ practice: 3 key notes
GI leader to know: Dr. Stephen Hutto of NorthPark Medical Plaza
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
